Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
15 participants
INTERVENTIONAL
2003-11-30
2005-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effects of Smell on Mood and Physical Responses
NCT00097253
Floatation-REST (Reduced Environmental Stimulation Therapy) for Anxiety and Depression
NCT03899090
A Pilot Study of Cranial Electrotherapy Stimulation[CES] for Generalized Anxiety Disorder
NCT00539357
Intervention Effect of Transcranial Alternating Current Stimulation(tACS) on Anxiety Disorder
NCT06026826
Auricular Acupuncture vs. Progressive Muscle Relaxation in Patients With Anxiety Disorders or Major Depressive Disorder.
NCT02340351
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
SINGLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Odorant Cue
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* GAD must be the primary active psychiatric disorder.
* GAD determined via the Mini International Neuropsychiatric Interview (MINI).
Exclusion Criteria
* Actively abusing alcohol.
* Illicit substances.
* Currently using rapid-acting anxiolytic agents (e.g. benzodiazepines, hydroxyzine).
* Started an antidepressant, antipsychotic or mood stabilizing agent within three months of screening visit.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Emory University
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Philip T Ninan, MD
Role: PRINCIPAL_INVESTIGATOR
Emory University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Emory University School of Medicine
Atlanta, Georgia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
0860-2003
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.